Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)

Recruiting Phase 2 Interventional Study
Chronic Spontaneous Urticaria (CSU)
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 75
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
48 (estimated)
Sponsor
Keymed Biosciences Co.Ltd · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with CSU.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Voluntarily sign the Informed Consent Form. * Age ≥ 18 years old and ≤ 75 years old. * Patients with a diagnosis of CSU before screening visit, and the duration was ≥6 months. * Pruritus and wheals existed for more than 6 weeks before screening, despite regular H1-Antihistamin…
Contacts

Qian Jia

86+028-88610620

clinicaltrial@keymedbio.com

CONTACT